Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer

Abstract Although paclitaxel plus bevacizumab (PB) therapy is an effective chemotherapeutic regimen for HER2-negative advanced breast cancer (ABC), predictive markers for its effectiveness remain undefined. We investigated the usefulness of systemic immunity markers associated with lymphocytes as pr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shogo Nakamoto, Masahiko Ikeda, Shinichiro Kubo, Mari Yamamoto, Tetsumasa Yamashita, Akifumi Notsu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/14dd1034bcb343bd9620773f8414331d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:14dd1034bcb343bd9620773f8414331d
record_format	dspace
spelling	oai:doaj.org-article:14dd1034bcb343bd9620773f8414331d2021-12-02T11:39:43ZSystemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer10.1038/s41598-021-85948-22045-2322https://doaj.org/article/14dd1034bcb343bd9620773f8414331d2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85948-2https://doaj.org/toc/2045-2322Abstract Although paclitaxel plus bevacizumab (PB) therapy is an effective chemotherapeutic regimen for HER2-negative advanced breast cancer (ABC), predictive markers for its effectiveness remain undefined. We investigated the usefulness of systemic immunity markers associated with lymphocytes as predictive markers for PB therapy in patients with HER2-negative ABC. We retrospectively reviewed data from 114 patients with HER2-negative ABC who underwent PB therapy from November 2011 to December 2019. We calculated the absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) as representative systemic immunity markers. The time to treatment failure (TTF) and overall survival (OS) of the patients with high ALC, low NLR, and high LMR were significantly longer compared with those of the patients with low ALC, high NLR, and low LMR. A multivariable analysis revealed that high ALC, low NLR, and low PLR were independent predictors for TTF and high ALC, low NLR, and high LMR were independent predictors for OS. Systemic immunity markers were significantly associated with longer TTF and OS in patients who underwent PB therapy and may represent predictive markers for PB therapy in patients with HER2-negative ABC.Shogo NakamotoMasahiko IkedaShinichiro KuboMari YamamotoTetsumasa YamashitaAkifumi NotsuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Shogo Nakamoto Masahiko Ikeda Shinichiro Kubo Mari Yamamoto Tetsumasa Yamashita Akifumi Notsu Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer
description	Abstract Although paclitaxel plus bevacizumab (PB) therapy is an effective chemotherapeutic regimen for HER2-negative advanced breast cancer (ABC), predictive markers for its effectiveness remain undefined. We investigated the usefulness of systemic immunity markers associated with lymphocytes as predictive markers for PB therapy in patients with HER2-negative ABC. We retrospectively reviewed data from 114 patients with HER2-negative ABC who underwent PB therapy from November 2011 to December 2019. We calculated the absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) as representative systemic immunity markers. The time to treatment failure (TTF) and overall survival (OS) of the patients with high ALC, low NLR, and high LMR were significantly longer compared with those of the patients with low ALC, high NLR, and low LMR. A multivariable analysis revealed that high ALC, low NLR, and low PLR were independent predictors for TTF and high ALC, low NLR, and high LMR were independent predictors for OS. Systemic immunity markers were significantly associated with longer TTF and OS in patients who underwent PB therapy and may represent predictive markers for PB therapy in patients with HER2-negative ABC.
format	article
author	Shogo Nakamoto Masahiko Ikeda Shinichiro Kubo Mari Yamamoto Tetsumasa Yamashita Akifumi Notsu
author_facet	Shogo Nakamoto Masahiko Ikeda Shinichiro Kubo Mari Yamamoto Tetsumasa Yamashita Akifumi Notsu
author_sort	Shogo Nakamoto
title	Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer
title_short	Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer
title_full	Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer
title_fullStr	Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer
title_full_unstemmed	Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer
title_sort	systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in her2 negative advanced breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/14dd1034bcb343bd9620773f8414331d
work_keys_str_mv	AT shogonakamoto systemicimmunitymarkersassociatedwithlymphocytespredictthesurvivalbenefitfrompaclitaxelplusbevacizumabinher2negativeadvancedbreastcancer AT masahikoikeda systemicimmunitymarkersassociatedwithlymphocytespredictthesurvivalbenefitfrompaclitaxelplusbevacizumabinher2negativeadvancedbreastcancer AT shinichirokubo systemicimmunitymarkersassociatedwithlymphocytespredictthesurvivalbenefitfrompaclitaxelplusbevacizumabinher2negativeadvancedbreastcancer AT mariyamamoto systemicimmunitymarkersassociatedwithlymphocytespredictthesurvivalbenefitfrompaclitaxelplusbevacizumabinher2negativeadvancedbreastcancer AT tetsumasayamashita systemicimmunitymarkersassociatedwithlymphocytespredictthesurvivalbenefitfrompaclitaxelplusbevacizumabinher2negativeadvancedbreastcancer AT akifuminotsu systemicimmunitymarkersassociatedwithlymphocytespredictthesurvivalbenefitfrompaclitaxelplusbevacizumabinher2negativeadvancedbreastcancer
_version_	1718395686713556992

Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer

Ejemplares similares